A Phase 2 Study to Evaluate DNTH103 in Adults With Generalized Myasthenia Gravis (MAGIC)
← catalyst calendarSponsored by Dianthus Therapeutics (industry) · DNTH — their whole pipeline →.
Phase
Phase 2
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Quadruple · Treatment
Enrollment
65actual
Sites
56
Countries
Argentina, Canada, Czechia +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-02-23 | actual | When the study began enrolling |
| Primary completion | 2025-07-28 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Oct 2028 | estimated | The whole study's end, after follow-up |
| First posted | 2024-02-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-27 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Myasthenia Gravis, Generalized
Interventions
- Drug: Claseprubart — also filed as DNTH103
- Drug: Placebo
Primary outcome
what the primary-completion date above is the date OFIncidence of Treatment-Emergent Adverse Events (TEAEs) and Treatment-Emergent Serious Adverse Events (SAEs)
measured Baseline (Day 1) to Week 13
Permalink · DNTH's whole pipeline · Catalyst calendar · Every registered study · What changed